Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Bayard L. Powell"'
Autor:
Susan Lyerly, Megan Manuel, Rupali Bhave, Leslie R. Ellis, Ryan Woods, Timothy S. Pardee, Mary Beth Seegars, Bayard L. Powell, Dianna S. Howard, Sarah Dralle
Publikováno v:
Journal of Hematology
Background: Resistance to therapy and a poor outcome characterize relapsed or refractory acute myeloid leukemia (AML). There is a clear need for additional palliative approaches with acceptable toxicities. Vincristine sulfate liposome injection (VSLI
Autor:
Geoffrey L. Uy, Maria R. Baer, Wendy Stock, Weiqiang Zhao, Ellen K. Ritchie, Richard A. Larson, Jennifer Le-Rademacher, Heidi D. Klepin, Richard Stone, Susan A. Geyer, Ben L. Sanford, Karla V. Ballman, Drew K. Seisler, Libby Storrick, Bayard L. Powell, Guido Marcucci, Brittny Major-Elechi, Harvey J. Cohen
Publikováno v:
J Geriatr Oncol
Objective To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods We conducted a multisite companion
Publikováno v:
Future Oncology. 15:3197-3208
Devimistat (CPI-613®) is an intravenously administered, novel lipoate analog that inhibits two key tricarboxcylic acid (TCA) cycle enzymes, pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase complexes (KGDH). These complexes control TCA
Autor:
Jonathan E. Kolitz, Susan M. Christner, Michaela Liedtke, Richard Stone, Geoffrey L. Uy, Meir Wetzler, Jan H. Beumer, Lionel D. Lewis, Jun Yin, Matthew J Wieduwilt, Wendy Stock, Elizabeth Storrick, Richard A. Larson, Steven M. Devine, Ryan J. Mattison, Bayard L. Powell
Publikováno v:
Blood Advances
Key Points Dasatinib and dexamethasone induction then allogeneic hematopoietic cell transplantation was feasible and effective for untreated Ph+ ALL.Treatment failure was associated with BCR-ABL1 T315I mutation, the p210 BCR-ABL1 isoform, or isolated
Autor:
Susan Lyerly, Leslie R. Ellis, Rupali Bhave, Jeff W. Chou, Lance D. Miller, Megan Manuel, Kristin M. Pladna, Scott Isom, Sarah Dralle, Rebecca G. Anderson, Nathaniel J. Schramm, Timothy S. Pardee, Bayard L. Powell, Dianna S. Howard
Publikováno v:
SSRN Electronic Journal.
Devimistat is a novel TCA cycle inhibitor being studied in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML. A combined analysis of the phase I and II datasets was conducted to determine the optimal phase III d
Autor:
Leslie R. Ellis, Susan Lyerly, Dmitriy Berenzon, Megan Manuel, Wei Zhang, Dianna S. Howard, Timothy S. Pardee, Sarah Dralle, Bayard L. Powell, Rebecca G. Anderson, Jeff W. Chou, Scott Isom, Lance D. Miller, Kristin M. Pladna, Lais P. Ghiraldeli, Guangxu Jin, David D. Hurd
Publikováno v:
Clinical Cancer Research. 24:2060-2073
Purpose: CPI-613, a lipoate analogue that inhibits pyruvate dehydrogenase (PDH) and α-ketogluterate dehydrogenase (KGDH), has activity in patients with myeloid malignancies. This study explored the role of mitochondrial metabolism in chemotherapy re
Autor:
Bayard L. Powell, Elizabeth Forbes, Enzo Palma, Timothy S. Pardee, Qianqian Song, Rakhee Vaidya, Wei Zhang, Ashley Ballard
Publikováno v:
Blood. 138:2263-2263
Introduction: Chimeric antigen receptor-based T cell therapy (CAR-T) has shown great promise in B cell malignancies. CD30-targeted therapies like brentuximab vedotin have activity in T cell malignancies expressing CD30. There is interest in developin
Autor:
Rupali Bhave, Timothy S. Pardee, Leslie R. Ellis, Bayard L. Powell, Megan Manuel, Kristin M. Pladna, Dianna S. Howard, Susan Lyerly, Sarah Dralle
Publikováno v:
Blood. 136:24-25
Background: Acute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow characterized by resistance to treatment and dismal outcomes, especially in the elderly. Novel approaches are desperately needed. Exportin 1 (XPO1) is involved in
Autor:
Jessica Kohlschmidt, Dimitrios Papaioannou, John C. Byrd, Christopher J. Walker, Eunice S. Wang, Deedra Nicolet, Andrew J. Carroll, Shelley Orwick, Bayard L. Powell, Ann-Kathrin Eisfeld, Richard Stone, James S. Blachly, Jonathan E. Kolitz, Ramiro Garzon, Clara D. Bloomfield, Marius Bill, Krzysztof Mrózek
Publikováno v:
Blood. 136:40-41
Introduction: AML is a heterogeneous disease of mainly older pts, with a median age of 68 y at diagnosis. Previous studies have shown that age is one of the most important prognosticators for overall survival (OS) of AML pts. In addition, several cyt
Autor:
Dianna S. Howard, Vivek Mehta, Susan Lyerly, Bayard L. Powell, Timothy S. Pardee, Ian M. Bouligny, Scott Isom, Sarah Dralle, Megan Manuel, Leslie R. Ellis, Rupali Bhave
Publikováno v:
Leuk Res
The azanucleotide decitabine is used in the treatment of acute myeloid leukemia (AML). Studies have shown conflicting results with 10-day regimens used in previously untreated AML patients. Additionally, there is little data on 10-day decitabine regi